ArticleJournal of hematology & oncology2023

Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells.

Fanyi Meng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.